Report Scope:
This report covers the worldwide market for SNP genotyping, with the market segmented by technology and application. It provides an in-depth analysis of the SNP genotyping market, including estimates and trends through 2029. In this report, the market is divided into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029. This report also uses analytical frameworks such as PESTEL, examines the competitive landscape, and explores trends in ESG and funding.

Report Includes:

  • 37 data tables and 44 additional tables
  • An overview of the global market for single nucleotide polymorphism (SNP) genotyping
  • Analyses of global market trends, with data from 2021-2023, estimates for 2024, and projected CAGRs through 2029
  • Evaluation of the current market size and revenue growth prospects specific to SNP genotyping, along with a market share analysis by technology, application, and region
  • Discussion of the advantages of the most frequently used SNP genotyping techniques, such as Sequenom’s MassArray DNA analysis platform, Bruker’s MALDI-TOF array, SNP pyrosequencing, microarrays and gene chips, and Applied Biosystems’ (now part of Thermo Fisher Scientific) SNPlex and TaqMan
  • Analysis of the regulatory framework and policies affecting the industry
  • Discussion of the ESG practices of, as well as challenges for, companies
  • Analysis of the key companies’ market shares and their proprietary technologies, strategic alliances and patents
  • Company profiles of the leading players, including Agilent Technologies Inc., F. Hoffman-La Roche Ltd., Illumina Inc., Qiagen, and Thermo Fisher Scientific Inc.